11/24/2009

The FDA granted fast-track status for ARCA Biopharma's Gencaro, expediting review of the drug as a treatment for chronic heart failure. ARCA plans to submit a study this quarter for a special-protocol assessment by the FDA.

Full Story:
Reuters

Related Summaries